ReviewIndian journal of endocrinology and metabolism
Role of T3 in Management of Hypothyroidism.
Review in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of hypothyroidism is based on the assumption that levothyroxine monotherapy normalizes thyroid hormone homeostasis, rendering patients clinically and biochemically euthyroid. However, a subset of patients treated with levothyroxine (LT4) are dissatisfied as they continue to have symptoms such as fatigue, weight gain, and difficulty in concentration. Some patients do not achieve normalization of thyroid-stimulating hormone despite adherence to adequate LT4 dosing. It has been proposed that liothyronine (LT3) may benefit such patients. This review addresses the specific role of LT3 in the management of hypothyroidism with an emphasis on practical considerations and a focus on appropriate patient selection. It identifies clinical challenges where patient outcomes are improved by adding LT3 to LT4 therapy, including myxedema coma, preoperative management, and situations where swift resolution of hypothyroidism is warranted. Further, it addresses the challenges faced in dose titration of LT4 and LT3 and the importance of monitoring therapy with LT3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.